Dopamine, dopaminergic drugs and ocular hypertension.
The study refers to the clinical experiences performed with several D1 and D2 dopaminergic receptors agonists in 20 patients with high tension open angle glaucoma. The substances were administered topically as eye drops as well as an ocular eye bath. The parameter examined was intraocular pressure (IOP). The substances taken in consideration were: Dopamine, Ibopamine (dopamine analog), Fenoldopam and 3B90 (D1-receptor agonists) and Bromocriptine (dopaminergic agonist with higher affinity for D2 than for D1-receptors). It has been shown that all selective D1-receptors agonists induce a significant increase in IOP only in eyes with hydrodynamic disorders (p < 0.001). Such hypertensive effects could not be antagonized either by topically administered dopaminergic antagonists (Sulpiride, D2-receptors antagonist, and Haloperidol, non-selective dopaminergic antagonist) or by the pretreatment with the commonly used topical antiglaucomatous drugs. The only substance which proved able to inhibit the IOP increase induced by the D1-receptors agonists was the D1-selective antagonist SCH-23390, suggesting that IOP increase may be a result of a stimulation of the D1-receptors. The authors hypothesize that dopaminergic system may play a role in the regulation of aqueous humor hydrodynamics.
Virno
M
M
Department of Ocular Physio-Pharmacology, University of Rome La Sapienza, Italy.
Gazzaniga
A
A
Taverniti
L
L
Pecori Giraldi
J
J
De Gregorio
F
F
D000328:Adult; D000368:Aged; D004298:Dopamine / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D018492:Dopamine Antagonists; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism
D015259:Dopamine Agents; D018492:Dopamine Antagonists; D009883:Ophthalmic Solutions; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D004298:Dopamine